We share your passion for science. Promega is committed to excellence in technologies to assess key processes in PROTAC-induced protein degradation: compound binding and permeability, ternary complex formation, ubiquitination, and trafficking to proteasome. Assay live cells in kinetic mode to determine target protein degradation rates, DC50 potency values, and recovery profiles. Let’s collaborate.
Generian is developing therapies that restore cellular function, amplifying natural signaling networks to reverse the course of disease. Generian's small molecules are designed to inhibit specific E3 ligase substrate-binding complexes, thereby preventing the degradation of beneficial target proteins and enhancing downstream cellular responses.
Generian is using its proprietary platform to advance its first-in-class programs for diseases with unmet need. Generian is exploring partnership opportunities for new target discovery to further develop this powerful platform.